rs45574238

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_000489.6(ATRX):​c.288A>G​(p.Lys96Lys) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00772 in 1,196,425 control chromosomes in the GnomAD database, including 556 homozygotes. There are 2,566 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.012 ( 57 hom., 410 hem., cov: 23)
Exomes 𝑓: 0.0073 ( 499 hom. 2156 hem. )

Consequence

ATRX
NM_000489.6 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: 2.21

Publications

3 publications found
Variant links:
Genes affected
ATRX (HGNC:886): (ATRX chromatin remodeler) The protein encoded by this gene contains an ATPase/helicase domain, and thus it belongs to the SWI/SNF family of chromatin remodeling proteins. This protein is found to undergo cell cycle-dependent phosphorylation, which regulates its nuclear matrix and chromatin association, and suggests its involvement in the gene regulation at interphase and chromosomal segregation in mitosis. Mutations in this gene are associated with X-linked syndromes exhibiting cognitive disabilities as well as alpha-thalassemia (ATRX) syndrome. These mutations have been shown to cause diverse changes in the pattern of DNA methylation, which may provide a link between chromatin remodeling, DNA methylation, and gene expression in developmental processes. Multiple alternatively spliced transcript variants encoding distinct isoforms have been reported. [provided by RefSeq, Jul 2017]
ATRX Gene-Disease associations (from GenCC):
  • alpha thalassemia-X-linked intellectual disability syndrome
    Inheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics
  • ATR-X-related syndrome
    Inheritance: XL Classification: DEFINITIVE Submitted by: ClinGen
  • intellectual disability-hypotonic facies syndrome, X-linked, 1
    Inheritance: XL Classification: MODERATE Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.53).
BP6
Variant X-77696659-T-C is Benign according to our data. Variant chrX-77696659-T-C is described in ClinVar as Benign. ClinVar VariationId is 93136.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=2.21 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.1 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ATRXNM_000489.6 linkc.288A>G p.Lys96Lys synonymous_variant Exon 5 of 35 ENST00000373344.11 NP_000480.3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ATRXENST00000373344.11 linkc.288A>G p.Lys96Lys synonymous_variant Exon 5 of 35 1 NM_000489.6 ENSP00000362441.4 P46100-1

Frequencies

GnomAD3 genomes
AF:
0.0115
AC:
1291
AN:
111851
Hom.:
54
Cov.:
23
show subpopulations
Gnomad AFR
AF:
0.00204
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.105
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000553
Gnomad SAS
AF:
0.00185
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00130
Gnomad OTH
AF:
0.0326
GnomAD2 exomes
AF:
0.0295
AC:
5351
AN:
181126
AF XY:
0.0204
show subpopulations
Gnomad AFR exome
AF:
0.00191
Gnomad AMR exome
AF:
0.190
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000726
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00111
Gnomad OTH exome
AF:
0.0220
GnomAD4 exome
AF:
0.00732
AC:
7935
AN:
1084520
Hom.:
499
Cov.:
27
AF XY:
0.00612
AC XY:
2156
AN XY:
352286
show subpopulations
African (AFR)
AF:
0.00222
AC:
58
AN:
26104
American (AMR)
AF:
0.183
AC:
6413
AN:
35030
Ashkenazi Jewish (ASJ)
AF:
0.0000519
AC:
1
AN:
19252
East Asian (EAS)
AF:
0.0000333
AC:
1
AN:
30068
South Asian (SAS)
AF:
0.00141
AC:
75
AN:
53379
European-Finnish (FIN)
AF:
0.0000494
AC:
2
AN:
40473
Middle Eastern (MID)
AF:
0.000493
AC:
2
AN:
4060
European-Non Finnish (NFE)
AF:
0.00121
AC:
1004
AN:
830492
Other (OTH)
AF:
0.00830
AC:
379
AN:
45662
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.492
Heterozygous variant carriers
0
264
528
792
1056
1320
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
128
256
384
512
640
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0116
AC:
1298
AN:
111905
Hom.:
57
Cov.:
23
AF XY:
0.0120
AC XY:
410
AN XY:
34149
show subpopulations
African (AFR)
AF:
0.00204
AC:
63
AN:
30895
American (AMR)
AF:
0.105
AC:
1110
AN:
10523
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
2648
East Asian (EAS)
AF:
0.000555
AC:
2
AN:
3604
South Asian (SAS)
AF:
0.00186
AC:
5
AN:
2693
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
6047
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
217
European-Non Finnish (NFE)
AF:
0.00130
AC:
69
AN:
53067
Other (OTH)
AF:
0.0322
AC:
49
AN:
1524
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
40
80
121
161
201
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00742
Hom.:
79
Bravo
AF:
0.0224

ClinVar

Significance: Benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
Feb 11, 2014
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jun 21, 2013
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Alpha thalassemia-X-linked intellectual disability syndrome Benign:2
Sep 16, 2020
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Inborn genetic diseases Benign:1
Apr 08, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.53
CADD
Benign
9.2
DANN
Benign
0.73
PhyloP100
2.2
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=93/7
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs45574238; hg19: chrX-76952147; COSMIC: COSV64869694; COSMIC: COSV64869694; API